Benchmarking is an important aspect of any business, and the clinical trial industry is no exception.
On Wednesday morning, the Metrics Champion Consortium hosted a workshop entitled “MCC Clinical Trial Performance Metrics—Improve Timelines, Cost, and Quality to Enhance CRO and Sponsor Performance in Clinical Outsourcing Collaborations.”
The workshop faculty featured:
· Guy Mascaro, President, Metrics Champion Consortium
· Nagaraja Srivatsan, Senior Vice President, Head of Life Sciences North America, Cognizant
· Krishnan Rajagopalan, PhD, Global Head of Life Sciences BPO, Cognizant
· David Zuckerman, President, Customized Improvement Strategies, LLC
· Amanda Sax, Senior Director, Clinical Data Management, Astrazeneca
The focus of the workshop was MCC’s clinical trial performance metrics blinded database initiative. The database is designed as a way for CROs and pharmaceutical, biotech, and device companies to compare themselves and their work to others in the industry through the use of 43 different metrics. The organization has attempted to develop bilateral metrics—metrics that take into consideration both sides of the equation between two partners.
“Our goal was to develop standardized performance metrics that both sets of organizations can agree to, drive towards, and focus on,” Mascaro said during an interview with Applied Clinical Trials. “We want to deliver the kinds of results and information that both organizations need to optimize the way they work together to improve efficiencies, cost effectiveness, and all those wonderful things necessary for a clinical trial or a series of clinical trials.”
The MCC’s goal is to provide a place for its members to consistently update and review benchmarking metrics in real time. The first step towards completing its goal and going live with the project will occur in June when a finished concept, featuring dummy data, is released for review. Following the mid-year test, the organization will develop a pilot program among a handful of large to mid-sized biotech companies and CROs for the first round of the blinded database pilot program, complete with real data. The MCC is hopeful to have a working database with up to 10 members by the end of the year. Over the next few years the database will continue to grow and improvements will be made to its functionality.
Once the database is up and running “companies would probably look at the data on a quarterly basis,” Mascaro said. “Compare that to what they do now, which is historically on an annual basis. Even then they are only reviewing their own database.
“We are attempting to take something that is very complex and provide a framework by which there can be a great understanding and a great effort towards working together as partners.”
During the workshop, Mascaro gave an update on the database’s development; Srivatsan and Rajagopalan discussed the use of data from an analytical standpoint; and Sax presented a case study on how the use of data can improve efficiencies and drive effectiveness.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.